Apogee Therapeutics, Inc.'s APG777 shows promising week-16 efficacy and dosing potential, targeting the AT market. Click for ...

AD and psoriasis were once thought to be opposites in terms of immune response, with AD linked to a Th2-dominant pathway and ...

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...

Apogee Therapeutics (NASDAQ:APGE) stock fell on Monday despite the announcement that it met its main goal in part A of its ...

Apogee Therapeutics shares soared in premarket trading Monday after the company said it received positive trial data for its atopic dermatitis treatment. Shares traded 36% higher ahead of the morning ...

Apogee Therapeutics’ anti-IL-13 antibody has been tied to a 71% reduction in eczema severity after 16 weeks, hitting the main ...

Apogee's APG777 showed a 71% drop in eczema severity and strong itch relief in a Phase 2 trial for atopic dermatitis. Part B ...

A focused update to AAD’s adult AD guidelines recommends tapinarof, roflumilast, lebrikizumab, and nemolizumab based on ...

Shares of Apogee Therapeutics, Inc. APGE +46.5% + Free Alerts rose sharply in today's pre-market trading after the company ...

A recent study found that teens who view cannabis and e-cigarette posts on social media are at risk. The Keck School of ...

Intermittent treatment with pimecrolimus over 1 year significantly reverses corticosteroid-induced skin atrophy and ...

Spongiotic dermatitis describes skin inflammation that causes swelling, redness, and itching. It's most often associated with ...